Latest News

Nivolumab combined with ipilimumab safe as first-line therapy for lung cancer patients

Combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a consistent safety profile in special populations with advanced non-small cell lung cancer (NSCLC), according to research presented today by at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.

Source link

Related posts

Lemon Water Benefits: Weight Loss And 6 Other Advantages Of Drinking Solution


Parents Can Help Their Sleep-Deprived Teens


New artificial intelligence-based method predicts treatment effectiveness


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy